Skip to main content
SpringerLink
Log in

Neoadjuvante Chemotherapie beim High-risk-Urothelkarzinom des oberen Harntraktes: aktuelle Evidenzlage

Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence

  • Journal Club
  • Published:
Die Urologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Adibi M, Youssef R, Shariat SF et al (2012) Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 19:1060–1066

    Article  PubMed  Google Scholar 

  2. Bajorin DF, Witjes JA, Gschwend JE et al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 384:2102–2114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Birtle A, Johnson M, Chester J et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 395:1268–1277

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Coleman JA, Yip W, Wong NC et al (2023) Multicenter phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma. J Clin Oncol 41(8):1618–1625. https://doi.org/10.1200/JCO.22.00763

    Article  CAS  PubMed  Google Scholar 

  5. Herout R, Baunacke M, Flegar L et al (2023) Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019. World J Urol 41:127–133

    Article  PubMed  Google Scholar 

  6. Margulis V, Puligandla M, Trabulsi EJ et al (2020) Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. J Urol 203:690–698

    Article  PubMed  Google Scholar 

  7. Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233

    Article  PubMed  Google Scholar 

  8. Necchi A, Martini A, Raggi D et al (2022) A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol 40:10.e1–10.e6

    Article  CAS  PubMed  Google Scholar 

  9. Papachristofilou A, Bedke J, Hayoz S et al (2022) Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial. Lancet Oncol 23:1441–1450

    Article  CAS  PubMed  Google Scholar 

  10. Porten S, Siefker-Radtke AO, Xiao L et al (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120:1794–1799

    Article  PubMed  Google Scholar 

  11. Roupret M, Babjuk M, Burger M et al (2021) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79:62–79

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Deutschland

    Christian Bolenz & Friedemann Zengerling

Authors
  1. Christian Bolenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Friedemann Zengerling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christian Bolenz.

Ethics declarations

Interessenkonflikt

C. Bolenz und F. Zengerling geben an, dass kein Interessenkonflikt besteht.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bolenz, C., Zengerling, F. Neoadjuvante Chemotherapie beim High-risk-Urothelkarzinom des oberen Harntraktes: aktuelle Evidenzlage. Urologie 62, 522–524 (2023). https://doi.org/10.1007/s00120-023-02086-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-023-02086-5

Search

Navigation